Ploemacher et al. investigated CXCR4 expression in adult AML patients and found that patients with high CXCR4 expression had a significantly lower survival rate and a higher likelihood of relapse, with a median relapse-free survival of 8.3 months [11]. Here, CXCR4 is linked to acute myeloid leukemia.